The accumulation of fluid in the pleural space, known as pleural effusion, represents a common yet clinically diverse condition linked to heart failure, infections, malignancies, and autoimmune disorders. Accurate diagnosis is essential, as the underlying cause dictates prognosis and therapeutic strategy. Modern approaches to pleural effusion treatment begin with imaging and thoracentesis, allowing both symptom relief and fluid analysis to determine etiology. Management may be as straightforward as diuretic therapy in heart failure or as complex as pleurodesis or indwelling catheter placement in malignant effusions. In infectious causes such as empyema, prompt drainage combined with antimicrobial therapy is critical to prevent complications. Advances in ultrasound-guided procedures have increased safety and diagnostic yield, reducing reliance on more invasive approaches. Minimally invasive thoracoscopy provides opportunities for both biopsy and therapeutic intervention in uncertain cases. Alongside procedural care, attention to patient comfort, recurrence prevention, and long-term monitoring is vital. Recent research into biomarkers is enhancing differentiation between benign and malignant effusions, supporting earlier and more targeted interventions. By combining diagnostic precision, effective therapeutic options, and individualized patient care, pleural effusion treatment continues to advance toward better outcomes, improved quality of life, and reduced healthcare burden.
Title : Global warming and increasing respiratory illnesses
Yazdan Mirzanejad, University of British Columbia, Canada
Title :
Saurabh Chattopadhyay, University of Kentucky, United States
Title : Risk factors for mycobacterium avium complex infections in patients with chronic obstructive pulmonary disease
Alizaman Sadigov, Medical University, United States
Title : Managing integration and interoperability in transformed pulmonology, respiratory medicine and lung health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Oncology (PPO) to be set up via precision oncology strategy for cancer care team: Developing targeted lung cancer therapy and advancing personalized cancer care
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Advancements in pulmonology and respiratory care through the view of Personalized and Precision Medicine (PPM) and biodesign-driven translational applications
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation